Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome

• DOI: 10.1016/j.jacl.2023.10.002
• Publication Date: 2023-10-05T06:19:52Z
• Authors: Carlos Escobar; Vivencio Barrios; Angel Cequier; Juan Cosin-Sales; Jose Seijas; Juan José Gómez D...; Vicente Arrarte; Jose Tuñon; Maciej Banach
• Keywords: PCSK9 inhibitors; Control; LDL cholesterol; Statins; Acute coronary syndrome; Ezetimibe; 3. Good health

In 2020, the Spanish Society of Cardiology published a consensus to improve lipid control in secondary prevention patients. This study was aimed to assess the impact of the implementation of this consensus in clinical practice.Non-interventional, national and multicenter study, with a prospective and retrospective design in two cohorts. Implementation of the consensus was performed on the prospective cohort. Prospective cohort included patients with acute coronary syndrome (ACS) from December 2020 to March 2022 and were followed-up for 3 months. Retrospective cohort included patients with ACS in the same hospital, matched for main baseline clinical characteristics, between August 2019 to February 2020, with a follow-up of 3 months. Additionally, patients were included if they had previously received lipid-lowering therapy and LDL cholesterol (LDL-C) was >55 mg/dL.A total of 516 patients were included (245 in the prospective cohort and 271 in the retrospective cohort). Overall, mean age was 67.9 ± 11.4 years, 73.8 % were men, and 35.8 % had diabetes. At discharge, 98.4 % and 98.9 %, respectively (P = 0.71) were taking statins (90.6% vs 88.9 %; P = 0.564 high intensity statins), 58.4% vs 33.2 %; P<0.001 ezetimibe, 1.2% vs 0.4 %; P = 0.35 PCSK9 inhibitors. During the follow-up, the dose of statins was increased in 11.4% vs 3.3 % (P<0.001), and ezetimibe was added in 25.7% vs 25.8 % (P = 0.976). At study end, significantly more patients achieved LDL-C <55 mg/dL in the prospective cohort (45.6% vs 33.5 %; P = 0.013).The implementation of the Spanish lipid consensus was associated with a significant improvement of LDL-C control after only 3 months.